ATE549019T1 - 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung - Google Patents

1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung

Info

Publication number
ATE549019T1
ATE549019T1 AT09172285T AT09172285T ATE549019T1 AT E549019 T1 ATE549019 T1 AT E549019T1 AT 09172285 T AT09172285 T AT 09172285T AT 09172285 T AT09172285 T AT 09172285T AT E549019 T1 ATE549019 T1 AT E549019T1
Authority
AT
Austria
Prior art keywords
acetylü
adamant
ylamino
carbonitrile
pyrrolidine
Prior art date
Application number
AT09172285T
Other languages
English (en)
Inventor
James Kowalski
Jay Lakshman
Abu Serajuddin
Yatindra Joshi
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37532821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE549019T1 publication Critical patent/ATE549019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
AT09172285T 2005-06-10 2006-06-08 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung ATE549019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971905P 2005-06-10 2005-06-10
US69030905P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
ATE549019T1 true ATE549019T1 (de) 2012-03-15

Family

ID=37532821

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06772653T ATE444748T1 (de) 2005-06-10 2006-06-08 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
AT09172285T ATE549019T1 (de) 2005-06-10 2006-06-08 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06772653T ATE444748T1 (de) 2005-06-10 2006-06-08 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung

Country Status (32)

Country Link
US (2) US20100021539A1 (de)
EP (2) EP1898904B1 (de)
JP (7) JP5579986B2 (de)
KR (1) KR101312812B1 (de)
AR (1) AR054383A1 (de)
AT (2) ATE444748T1 (de)
AU (1) AU2006257947B2 (de)
BR (1) BRPI0613499B8 (de)
CA (1) CA2610422A1 (de)
CY (1) CY1109719T1 (de)
DE (1) DE602006009656D1 (de)
DK (1) DK1898904T3 (de)
EC (1) ECSP077987A (de)
ES (2) ES2385129T3 (de)
GT (1) GT200600246A (de)
HR (1) HRP20090680T1 (de)
IL (1) IL187420A (de)
JO (1) JO2584B1 (de)
MA (1) MA29564B1 (de)
MX (1) MX2007015677A (de)
MY (1) MY152185A (de)
NO (1) NO343043B1 (de)
NZ (1) NZ563447A (de)
PE (3) PE20110057A1 (de)
PL (2) PL1898904T3 (de)
PT (2) PT2191824E (de)
RU (1) RU2423124C2 (de)
SA (1) SA06270171B1 (de)
SI (1) SI1898904T1 (de)
TN (1) TNSN07464A1 (de)
TW (1) TWI381835B (de)
WO (1) WO2006135723A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894251B (zh) * 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
ATE537141T1 (de) 2004-02-05 2011-12-15 Kyorin Seiyaku Kk Bicycloesterderivat
CN1960992B (zh) * 2004-06-02 2011-10-19 桑多斯股份公司 晶体形式的美罗培南中间体
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP5305909B2 (ja) * 2005-09-21 2013-10-02 フォーエスシー アクチエンゲゼルシャフト ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩
NZ567357A (en) * 2005-10-31 2011-05-27 Janssen Pharmaceutica Nv Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
WO2007078726A2 (en) * 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
AU2007224066B2 (en) 2006-03-08 2011-10-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
JP5318757B2 (ja) * 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
CN101568544B (zh) * 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
ATE550319T1 (de) 2007-03-22 2012-04-15 Kyorin Seiyaku Kk Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102119139A (zh) 2008-08-07 2011-07-06 杏林制药株式会社 二环[2.2.2]辛胺衍生物的制造方法
MX370599B (es) 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
US20120029032A1 (en) * 2009-03-27 2012-02-02 Kyorin Pharmaceutical Co., Ltd. Matrix-type sustained release preparation containing basic additive
SG174504A1 (en) * 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
IN2012DN03271A (de) * 2009-10-23 2015-10-23 Merck Sharp & Dohme
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
EP2547339A1 (de) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Kombination eines gpr119-agonisten und des dpp-iv-hemmers linagliptin zur verwendung bei der behandlung von diabetes und zugehöriger erkrankungen
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
SG188361A1 (en) * 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
EP2468268B1 (de) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Kombinationszusammensetzung aus Vildagliptin und Gliclazid
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
TR201010683A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
EP2753328A1 (de) 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv-hemmerformulierungen
EP2572704A1 (de) 2011-09-22 2013-03-27 Sanovel Ilac Sanayi ve Ticaret A.S. Im Mund zerfallende Formulierungen mit Vildagliptin
US9174973B2 (en) * 2011-09-30 2015-11-03 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
PL2578208T3 (pl) 2011-10-06 2014-10-31 Sanovel Ilac Sanayi Ve Ticaret As Stałe formulacje dawkowane inhibitora DPP-IV
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
US20170014380A1 (en) 2014-03-06 2017-01-19 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Vildagliptin Formulation Process Under Inert Gas Atmosphere
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
RU2585378C1 (ru) * 2014-11-28 2016-05-27 Дмитрий Сергеевич Титов Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию вилдаглиптина и гликвидона
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
RU2602688C1 (ru) * 2015-06-29 2016-11-20 Елена Николаевна Якушева Способ моделирования состояния ингибирования функциональной активности гликопротеина-р ингибитором дипептидилпептидазы 4
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
BR112018013195A2 (pt) * 2015-12-28 2018-12-11 Wockhardt Ltd composição farmacêutica osmótica oral de vildagliptina
PL3512505T3 (pl) 2016-09-16 2023-08-07 Galenicum Health S.L.U. Farmaceutyczne kompozycje wildagliptyny
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
JP7225221B2 (ja) * 2017-09-19 2023-02-20 ダイアミド・メディカル・アクチボラゲット ガンマアミノ酪酸の新規製剤
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
BR112021024099A2 (pt) * 2019-05-29 2022-01-11 Abbott Healthcare Pvt Ltd Composição farmacêutica para diabetes mellitus
JP7461735B2 (ja) * 2019-12-02 2024-04-04 日本ジェネリック株式会社 ビルダグリプチン含有錠剤
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
WO2021234430A1 (en) * 2020-05-17 2021-11-25 Lotus International Pte. Ltd. Modified release dosage form comprising vildagliptin and process for manufacturing the same
CN115054582B (zh) * 2022-08-08 2022-12-06 北京惠之衡生物科技有限公司 一种维格列汀片的制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
MY123337A (en) 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1140084A1 (de) * 1998-12-22 2001-10-10 Novo Nordisk A/S Neue formulierung
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
DK1248604T4 (da) * 2000-01-21 2012-05-21 Novartis Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
AU2001228309A1 (en) 2000-01-24 2001-08-07 Novo-Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001254763A1 (en) 2000-03-31 2001-10-08 Prosidion Limited Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
DK1308439T3 (da) 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
ATE407924T1 (de) 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
PE20021002A1 (es) 2001-02-02 2002-12-06 Takeda Chemical Industries Ltd Compuestos heterociclicos condensados
EE05643B1 (et) 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1406872B1 (de) 2001-06-20 2007-12-19 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
DE60209348T2 (de) 2001-06-20 2006-10-12 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
EP1404675B1 (de) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1426366A4 (de) 2001-09-14 2004-12-08 Mitsubishi Pharma Corp Thiazolidinderivate und deren medizinische verwendung
EP1463727A2 (de) 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclische verbindungen, bei denen es sich um inhibitoren des enzyms dpp-iv handelt
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
JP5105684B2 (ja) * 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
JP2004123738A (ja) * 2002-09-11 2004-04-22 Takeda Chem Ind Ltd 徐放性製剤
WO2004024184A1 (ja) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
DK1556362T3 (da) 2002-10-18 2008-06-09 Merck & Co Inc Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1782832A4 (de) * 2004-08-26 2009-08-26 Takeda Pharmaceutical Mittel zur behandlung von diabetes
EP1807066A1 (de) * 2004-10-25 2007-07-18 Novartis AG Kombination aus dpp-iv-hemmer, ppar-antidiabetikum und metformin
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation

Also Published As

Publication number Publication date
JP2015091864A (ja) 2015-05-14
TWI381835B (zh) 2013-01-11
BRPI0613499B8 (pt) 2021-05-25
ES2334261T3 (es) 2010-03-08
ECSP077987A (es) 2008-01-23
EP2191824B1 (de) 2012-03-14
EP1898904A2 (de) 2008-03-19
NO20080177L (no) 2008-02-15
MX2007015677A (es) 2009-02-20
PT2191824E (pt) 2012-06-18
PE20150728A1 (es) 2015-06-01
AR054383A1 (es) 2007-06-20
RU2423124C2 (ru) 2011-07-10
BRPI0613499A2 (pt) 2011-01-11
CA2610422A1 (en) 2006-12-21
JO2584B1 (en) 2011-02-27
PL2191824T3 (pl) 2012-08-31
US20100021539A1 (en) 2010-01-28
HK1117037A1 (en) 2009-01-09
JP5579986B2 (ja) 2014-08-27
SI1898904T1 (sl) 2010-01-29
ATE444748T1 (de) 2009-10-15
JP2018172392A (ja) 2018-11-08
BRPI0613499A8 (pt) 2019-01-15
BRPI0613499B1 (pt) 2020-07-14
NO343043B1 (no) 2018-10-15
KR101312812B1 (ko) 2013-09-27
TNSN07464A1 (en) 2009-03-17
DK1898904T3 (da) 2009-12-21
PT1898904E (pt) 2009-12-23
RU2007148241A (ru) 2009-07-20
IL187420A (en) 2013-01-31
PL1898904T3 (pl) 2010-03-31
GT200600246A (es) 2007-03-28
NZ563447A (en) 2012-02-24
AU2006257947B2 (en) 2010-06-10
PE20110057A1 (es) 2011-02-15
JP2013177428A (ja) 2013-09-09
US20110086096A1 (en) 2011-04-14
PE20070691A1 (es) 2007-08-06
JP2022058771A (ja) 2022-04-12
JP2016222675A (ja) 2016-12-28
EP2191824A1 (de) 2010-06-02
TW200726467A (en) 2007-07-16
JP2020055816A (ja) 2020-04-09
DE602006009656D1 (de) 2009-11-19
KR20080028364A (ko) 2008-03-31
EP1898904B1 (de) 2009-10-07
JP2008543773A (ja) 2008-12-04
AU2006257947A1 (en) 2006-12-21
WO2006135723A2 (en) 2006-12-21
MY152185A (en) 2014-08-29
MA29564B1 (fr) 2008-06-02
HK1143094A1 (en) 2010-12-24
CY1109719T1 (el) 2014-08-13
ES2385129T3 (es) 2012-07-18
SA06270171B1 (ar) 2010-03-08
WO2006135723A3 (en) 2007-07-05
IL187420A0 (en) 2008-02-09
HRP20090680T1 (hr) 2010-02-28

Similar Documents

Publication Publication Date Title
ATE444748T1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
ZA200802602B (en) Controlled release formulation
IL189856A0 (en) New formulation
DK1928882T3 (da) (s)-n-methylnaltrexon
ITMI20050728A1 (it) Formulazione innovativa
EP1951275A4 (de) Zusammensetzung gegen adipositas
BRPI0618398A2 (pt) artigo absorvente
DK1688111T3 (da) Absorberende artikel
NO20055686D0 (no) Sammensetning
DK1978944T3 (da) Blød-gelatine-kapselformulering
TWI370115B (en) New formulation
EP1897558A4 (de) Feste zubereitung
FR2881643B1 (fr) Composition matifiante comprenant de la perlite
BRPI0618396A2 (pt) artigo absorvente
ITFI20050094A1 (it) Opercolatrice perfezionata
GB0526419D0 (en) Formulation
DE602006006937D1 (de) Hosenträger
GB0517673D0 (en) Formulation
BRPI0618419A2 (pt) retorno rápido
EP1852499A4 (de) Neurotisationsförderndes agens
GB0518129D0 (en) Ramipril formulation
BRPI0618397A2 (pt) artigo absorvente
GB0501030D0 (en) Formulation
PL1928232T3 (pl) Stała formulacja
ITMI20051971A1 (it) Procedimento per la preparazione di - modafinil